Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catequentinib DDI Study with Itraconazole and Ticagrelor
NCT07438886Phase 1Not yet recruiting
- Sponsor
- Advenchen Laboratories
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of catequentinib in solid tumor, sponsored by Advenchen Laboratories. Primary endpoint: Pharmacokinetic parameters of AL3818 at 1 year. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
catequentinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07438886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07438886.